Background: The factors which contribute to length of stay variations for hospital discharges is the focus of an expanding body of international research. Methods: The study reported here is intended to facilitate an advancement of this research as the analysis described was undertaken on a unique multinational database within which over 3.3 million cases from 12 countries have been compiled in a standardised manner. Differences in length of stay both within and between countries were assessed for over 119,400 discharges within selected high-volume pathologies classified according to three alternative measures of hospital casemix. Results: The results show that irrespective of the casemix measure applied, substantial unexplained variation in hospital length of stay persists both within and between countries for the pathologies reviewed. Conclusions: These results suggest that, in addition to standardising for casemix, future research on length of stay variation should focus on additional potentially influential factors, including hearth system characteristics, medical practice variation and patient behaviour and expectations.
have approached this issue from a number of perspectives, including assessments of the incidence of common surgical procedures 1 and interhospital 2 and cross-national variations 3 ' 4 in length of stay (LOS) for selected pathologies. In particular, concerns with variations in LOS have led recent research studies to assess whether the observed variation can be controlled with standardisation for casemix. A US study of inter-hospital differences in LOS for hip fracture concluded that severity adjustment did little to control for the high level of variation observed. A similar conclusion was reached by a study of hospital care for three pathologies in Italy, Japan and the US which also applied a measure of severity to control for patient mix. 3 The study presented here advances this area of enquiry by estimating LOS variations bouS within and between selected countries for a number of high-volume pathologies. In addition, the influence of casemix on the LOS variation observed is estimated by assessing the explanatory effect of three measures on this variability. The casemix measures tested include two diagnosis-related group (DRG) classification systems and disease staging (DS) and the analysis is based on a multinational database compiled in a standardised manner and analysed in a central facility. The high-volume pathologies selected for analysis included three well-defined surgical DRGs [39 lens procedures, 198 cholecystectomy without common duct exploration (CDE), without complication/comorbidity (OC), and 119 vein ligation and stripping], and two medical DRGs [294 diabetes age >35 years and 122 circulatory disorders with acute myocardial infarction (AMI), withoutcardiovascular complications, discharged alive]. The data analysed in this paper were collected as part of the CAMISE (hospital use, casemix and severity) project, a European Union concerted action investigating the inter-relationships between hospital use, casemix measurement and severity assessment. Activity data on more than 4 million patient discharges from 12 European countries were compiled by this project. Following data collection, the database was standardised and assessed against a number of quality measures. Where the required data were available, the patient records were analysed according to the selected casemix measures. The DRG classification systems tested were originally developed with the objective of constructing patient classes homogeneous in terms of treatment process and resource consumption. Data required for DRG assignment include primary and secondary diagnoses, procedures performed, age, sex and discharge status. A number of DRG systems are currently in existence, including those developed for the US Health Care Financing Administration (HCFA). Version 10.0 of the HCFA DRG series which incorporates 489 patient groups is one of the measures included in the analysis presented here. A concern with improving the measurement of severity widiin the DRG classification framework resulted in the development of the all patient (AP)-refined DRGs which were developed with the objective of creating iso resource classes. While using the same core data for assignment, important departures from the HCFA DRGs include the elimination of the age £17 years split and the major CC split which resulted in the creation of consolidated DRGs (CDRGs). According to specific combinations of complications/co-morbidities, non-surgical procedures and age, four complexity classes (CAN) are defined within each CDRG; each record is therefore assigned to a CDRG and a CAN value. There are 1,439 CDRG plus CAN combinations defined within the APrefined DRGs.
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DS is a stand-alone system which first classifies discharges across 397 disease categories (DXCAT) and then assigns them to a stage widiin each disease category. Staging involves the classification of diseases according to increasing levels of severity as follows: stage 1 includes conditions with no complications or problems of minimal severity, stage 2 involves problems limited to an organ or system, with significant increased risk of complications, and stage 3 implies multiple-site involvement, general systemic involvement and poor prognosis.-* Stages are ordinal and discrete values reflect disease progression and prognosis within a disease. Stages are not comparable across diseases. Sub-stages may also be defined if additional specification of seventy is necessitated. Only diagnoses are necessary for assignment within DS; specific combinations of related diagnoses are used to assign to the relevant stage. DS is a multi-assignment system and, when co-morbidities exist, more than one disease stage combination is assigned. Prior to the presentation and discussion of results, the data collected and methods of analyses applied in this study will be briefly reviewed.
form format to the central facility at 1ASIST in Barcelona for analysis. As only one database from each country was to be included in the analysis, the most complete and representative data sets were selected from Belgium and Italy. Table I shows that this resulted in die compilation of an initial database of 3,682364 records from the 12 European countries. It must be recognised, however, that, as the provision of data was undertaken on a voluntary basis, rJiere was substantial variation between countries in the coverage of these databases at the national level. For example, for Italy, Russia and the UK, data from just one region were submitted. For Sweden, the data came from one county and the Slovak data covered 15 districts within three regions. The data submitted for Belgium represents just six mondis because the ministry indicated that these data were the most valid. Given that this research was focused on variations in hospital LOS for selected pathologies, the relationship between the source data and the respective national databases was considered outside the scope of the project. The discharges included in the final data set cannot therefore be assumed to be representative of all discharges nationally. Data processing and analysis of the combined data set proceeded as follows.
• Standardisation of data returns.
• Standardisation of the approach to coding diagnoses and procedures was required prior to clinical data validation as the selected casemix measures require morbidity data to be coded within ICD-9-CM. • Data quality assessment for administrative and clinical data.
• Standardisation of all database variables and values. b: 1990, 1991 and 1991, 1992 : only 1 year period included, but year is different depending on the hospital considered. 1991-1992: a 1 year period included, but not a natural year, some mondis of one year and some months of the next year. c: The period covers 6 months of 1991.
• Calculation of age in days at the time of admission (admission date minus birth date).
• Calculation of length of stay (LOS) (difference in days between discharge date and admission date).
• Final data quality edits, both for administrative and calculated variables and for clinical data. Given the objective of ensuring high standards of homogeneity for the aggregated data set, a number of exclusion criteria had to be specified which included the following.
• Records with no diagnoses coded were excluded. These cases amounted to around 1-3% per country database.
• Cases where the LOS value was not calculable due to errors in dates were excluded. These exclusions resulted in the elimination of 38,451 cases from the database.
• Cases were excluded with LOS = 0, where date of admission and discharge were the same and discharges were not dead/not transferred to another acute care hospital. Day case definition criteria are different across countries and some countries include day cases in the MBDS while others are more restrictive. As countries varied in whether or not day cases were reported with die discharge abstract data, in the interest of standardisation it was decided to exclude the 312,013 cases which qualified within this proxy of the day case definition. The final distribution of databases by country is shown in table 1, including the proportion of total hospitalisations accounted for by the discharges included in the analysis. In total, 3,331,900 cases from 12 countries were include in the final database. When the data set was finalised, the analysis with the three selected casemix measures was undertaken for all records with valid data. As the databases from Hungary and Slovakia did not include information on procedures performed, the discharges from these countries could only be grouped with DS. Following classification of all valid discharges, the grouping of invalid classes within each measure was edited. For each casemix measure and for each hospital and country database, average length of stay (ALOS) was calculated for the ten countries with the required data. Due to the non-normal distribution of the LOS variable, the geometric mean rather than the arithmetic mean was estimated.
11 " 14 As the geometric mean of LOS is little influenced by high outliers, this provided an alternative to the classical trimming on the right tail of the LOS distribution. Variation in ALOS was measured by means of the coefficient of variation (CV) for each casemix group.
For each of the pathologies selected for investigation, the following analyses were performed.
• Assessment of ALOS variation between country databases and the associated statistical significance. Because of the systematically higher LOSs by casemix group found for Russia, these data had to be excluded from the statistical tests applied across country databases.
• Assessment of ALOS variation among individual hospitals within each database and the associated statistical significance.
• Case breakdown by severity class within the DRG; for AP-refined DRGs these included combinations of CDRG plus CAN, while the DS analyses involved combinations of the principal diagnosis category (PDXCAT) plus staging. While generally up to three stages may be defined (stages 1, 2 and 3), for some PDXCAT (e.g. normal vaginal delivery) a stage 0 meaning no illness may be defined. Severity classes with enough cases were selected for the analysis.
• The ALOS analyses were repeated for each selected severity level. For the assessment of the statistical significance of ALOS differences among groups, analysis of variance (ANOVA) was used. Given the requirements for the ANOVA analysis and the estimation of the ALOS as the geometric mean, the dependent variable used is the log-transformed LOS. Because of the inequality of variances and/or inequality of cases observed among cells, all the analyses were also performed by means of the Kruskal-Wallis non-parametric test of differences of means for independent data. The significance level was set at p=0.05.
RESULTS
The presentation of results for the five selected pathologies in tables 2-6 addresses the effect of adjusting for different measures of casemix on observed differences in average length of stay. Taken together, there are over 119,400 discharges distributed across the five pathologies. ALOS is presented for each pathology for the HCFA DRGs, in addition to being disaggregated by APR-DRG class and DS class. Significance levels for LOS differences within and between countries are also presented. 1214, 50% were at the stage 1 level and 30.7% were at stage 2. The data on adult diabetes presented in table 5 show that a longer ALOS is generally in evidence for the second class/stage within the APR-DRG or DS systems, which is consistent with the fact that a higher level of severity would be expected at these levels. While intercountry differences in ALOS continue to be significant across die casemix measures, there is a higher level of success in controlling ALOS differences at the country level. For the HCFA DRGs, ALOS differences are controlled or marginally significant in France, The Netherlands and Russia. While ALOS differences in The Nedierlands and Russia are controlled for both classes within the APR-DRGs, die ALOS differences are shown to be not significant or marginally significant for France, Ireland, Sweden and the UK. For PDXCAT 1214, ALOS differences in The Nedierlands are again shown to be controlled or marginally significant for both stages, widi similar results being presented for France, Russia and die UK at stage 2. ALOS differences remain significant at the country level for Belgium, Italy, Portugal and Spain, irrespective of die type of casemix measure. HCFA DRG 122, circulatory disorders widi AMI, accounts for 22,732 discharges. Widiin PDXCAT 815 all discharges fall within stage 3, AMI, so the results for both DS and HCFA DRG 122 are the same and presented in the first column of table 6. Within the APR-DRGs, 88.7% of discharges are assigned to class 1 widiin CDRG 121 Table 4 (A)LOS: (average) length of stay; HCFA. health care financing administration; APR: all patient-refined; (C)DRG: (consolidated) diagnosis-re la ted group; DS: disease staging; PDXCAT: principal diagnosis category a: ANOVA/Kruskall-Wallis signifiance of ALOS difference between countries: * p<0.05, ** p<0.01, •*• p<0 001, ns: not significant while 8.4% are assigned to class 2. The trend for longer LOSs across countries for class 2 within CDRG 121 is indicative of the higher level of severity found at this level. While ALOS differences between countries are significant for all measures, there is some variation at the country level. Intracountry differences in ALOS are also significant for all countries for HCFA DRGs (and DS). The exceptions for APR-DRGs are The Netherlands, Russia and the UK where ALOS differences are found to be not significant at the class 2 level. The discussion section which follows provides an overview of the findings presented here.
DISCUSSION
The casemix analyses undertaken for the pathologies selected for consideration in this study show some interesting variation in LOS found at the international level. Notwithstanding a small number of exceptions, however, this variation was not fully controlled by the casemix measures applied. This finding is consistent with previous research studies in this area.
• While the small number of cases in which LOS differences were controlled do not seem to follow any obvious pattern, there is a tendency for these cases to arise in categories which split according to different measures of severity. The prevailing pattern emerging from these results, however, is that LOS differences persist both within and between countries for selected pathologies, irrespective of the application of casemix measures to control for severity. While the casemix techniques applied in this study facilitate the standardisation of comparisons at the hospital or country level, they clearly do not offer a complete explanation for the LOS differences observed. It must be recognised, however, that this was not necessarily the initial starting point for these measures. The challenge remains, therefore, to approach a more complete understanding of the factors not being controlled by the casemix measures applied here and which are contributing to the LOS differences observed for the selected pathologies.
CONCLUSION
The results of the analyses presented here for LOS differences within and between countries for selected pathologies indicate that some level of standardisation for medical practice variation can be achieved with the application of casemix measures. It is interesting, however, that the results produced by testing the HCFA DRGs, the APR-DRGs and the DS systems do not differ greatly according to the system of analysis. All of the measures applied here are based on limited data analysed at an aggregated level. These characteristics may be considered to be advantageous for the achievement of such objectives as the application of casemix measures in a management context. From the research results presented here, however, it is evident that the use of such measures of casemix are not sufficient to account for the differences in LOS observed for the high-volume pathologies studied both at the intra-and intercountry level. Previous research has indicated that such factors as health system organisation, physician practice and patient expectations and preferences may also have a role to play in explaining institutional and systemic differences in LOS. 1 ' 3 This study shows that a range of casemix measures can be successfully applied to a multinational database concerned with a range of pathologies treated in the hospital environment. While standardisation for casemix in this way may be useful for such initiatives as utilisation review and re- 
